Dublin, Oct. 27, 2017 (GLOBE NEWSWIRE) -- The "Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2010- 2017" report has been added to Research and Markets' offering.
The report provides a detailed understanding and analysis of how, why and on what terms companies enter discovery stage partnering deals. These deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors product or technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all discovery stage partnering deals announced since 2010 including financial terms where available including over 3,000 links to online deal records of actual discovery partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.
Key benefits
- In-depth understanding of discovery stage deal trends since 2010
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of discovery stage agreements with numerous real life case studies
- Insight into the terms included in a discovery stage agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope
- Trends in discovery stage dealmaking in the biopharma industry since 2010
- Analysis of discovery stage deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life discovery stage deals
- Access to over 3,000 discovery stage deals
- The leading discovery stage deals by value since 2010
- Most active discovery stage dealmakers since 2010
- The leading discovery stage partnering 2010
Contracts are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal type
- Specific therapy target
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Why do companies partner at discovery stage?
Chapter 3 - Discovery stage deal strategies and structure
Chapter 4 - Discovery stage partnering payment strategies
Chapter 5 - Trends in discovery stage deal making
Chapter 6 - Payment terms for discovery stage partnering
Chapter 7 - Leading discovery stage deals
Chapter 8 - Top 50 most active discovery stage dealmakers
Chapter 9 - Discovery stage partnering contracts directory
Chapter 10 - Discovery stage deal making by development stage
For more information about this report visit https://www.researchandmarkets.com/research/j3dp8v/global_discovery